Roche is paying $20 million upfront to secure rights to two degrader-antibody conjugates (DACs), developed by longtime ...

Bio (NASDAQ:IBIO) is seeking to narrow what it views as a growing “trust gap” between the promise of generative AI in drug discovery and the high cost and long timelines of bringing a drug to market, ...

Discover what were the top biotech deals that were signed in March 2026. From small molecules to antibodies, M&A activity was high.

C4 Therapeutics will receive $20m upfront in addition to milestone payments, with a potential $1bn in additional milestones.

Merck & Co. is rounding out its March deal flurry with an antibody discovery pact that could be worth as much as $838 million ...

Merck is partnering with Infinimmune in a deal worth up to $838 million to leverage AI-driven antibody discovery. Do you know ...

The drug, which Invivyd sees as a potential treatment and “targeted alternative” for the vaccine-hesitant, comes as measles ...

Trastuzumab pamirtecan, an investigational HER2-targeted antibody-drug conjugate, met the primary efficacy endpoint in a Phase 2 cohort of heavily pre-treated patients with HER2-expressing, recurrent ...

Agreement Focused on Developing DACs With Payloads For Two Oncology Targets, With an Option for a Third Target ...

Roche has joined its Big Pharma peers in the emerging degrader-antibody conjugate (DAC) space, paying C4 Therapeutics $20 ...

Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced a ...